237 related articles for article (PubMed ID: 16835378)
1. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of a phase I/II randomized, placebo-controlled trial of palifermin to prevent graft-versus-host disease (GVHD) after related donor allogeneic hematopoietic cell transplantation (HCT).
Levine JE; Blazar BR; DeFor T; Ferrara JLM; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1017-1021. PubMed ID: 18721764
[TBL] [Abstract][Full Text] [Related]
3. Palifermin is efficacious in recipients of TBI-based but not chemotherapy-based allogeneic hematopoietic stem cell transplants.
Goldberg JD; Zheng J; Castro-Malaspina H; Jakubowski AA; Heller G; van den Brink MR; Perales MA
Bone Marrow Transplant; 2013 Jan; 48(1):99-104. PubMed ID: 22750997
[TBL] [Abstract][Full Text] [Related]
4. Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
Jagasia MH; Abonour R; Long GD; Bolwell BJ; Laport GG; Shore TB; Durrant S; Szer J; Chen MG; Lizambri R; Waller EK
Bone Marrow Transplant; 2012 Oct; 47(10):1350-5. PubMed ID: 22327131
[TBL] [Abstract][Full Text] [Related]
5. The influence of palifermin (Kepivance) on oral mucositis and acute graft versus host disease in patients with hematological diseases undergoing hematopoietic stem cell transplant.
Nasilowska-Adamska B; Rzepecki P; Manko J; Czyz A; Markiewicz M; Federowicz I; Tomaszewska A; Piatkowska-Jakubas B; Wrzesien-Kus A; Bieniaszewska M; Duda D; Szydlo R; Halaburda K; Szczepinski A; Lange A; Hellman A; Robak T; Skotnicki A; Jedrzejczak WW; Walewski J; Holowiecki J; Komarnicki M; Dmoszynska A; Warzocha K; Marianska B
Bone Marrow Transplant; 2007 Nov; 40(10):983-8. PubMed ID: 17846600
[TBL] [Abstract][Full Text] [Related]
6. Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.
Nasilowska-Adamska B; Szydlo R; Rzepecki P; Czyz A; Tomaszewska A; Markiewicz M; Torosian T; Bieniaszewska M; Hellman A; Jedrzejczak WW; Holowiecki J; Komarnicki M; Warzocha K; Marianska B
Ann Transplant; 2011; 16(4):47-54. PubMed ID: 22210421
[TBL] [Abstract][Full Text] [Related]
7. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.
Alousi AM; Brammer JE; Saliba RM; Andersson B; Popat U; Hosing C; Jones R; Shpall EJ; Khouri I; Qazilbash M; Nieto Y; Shah N; Ahmed S; Oran B; Al Atrash G; Ciurea S; Kebriaei P; Chen J; Rondon G; Champlin RE
Biol Blood Marrow Transplant; 2015 May; 21(5):906-12. PubMed ID: 25667989
[TBL] [Abstract][Full Text] [Related]
8. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients.
Langner S; Staber P; Schub N; Gramatzki M; Grothe W; Behre G; Rabitsch W; Urban C; Linkesch W; Neumeister P
Bone Marrow Transplant; 2008 Aug; 42(4):275-9. PubMed ID: 18500368
[TBL] [Abstract][Full Text] [Related]
9. Safety, Pharmacokinetics, and Efficacy of Palifermin in Children and Adolescents with Acute Leukemias Undergoing Myeloablative Therapy and Allogeneic Hematopoietic Stem Cell Transplantation: A Pediatric Blood and Marrow Transplant Consortium Trial.
Morris J; Rudebeck M; Neudorf S; Moore T; Duerst R; Shah AJ; Graham M; Aquino V; Morris C; Olsson B
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1247-1256. PubMed ID: 26968792
[TBL] [Abstract][Full Text] [Related]
10. [Effect of BU and CY versus TBI and CY as conditioning regimens on the efficacy of haploidentical stem cell transplantation in patients with hematologic malignancy].
Shao Q; Han D; Liu D; Zheng X; Dong L; Wang Z; Ding L; Yan H; Wang H; Duan L
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):505-10. PubMed ID: 24985173
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
[TBL] [Abstract][Full Text] [Related]
12. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and marrow transplantation.
Nagler A; Rocha V; Labopin M; Unal A; Ben Othman T; Campos A; Volin L; Poire X; Aljurf M; Masszi T; Socie G; Sengelov H; Michallet M; Passweg J; Veelken H; Yakoub-Agha I; Shimoni A; Mohty M
J Clin Oncol; 2013 Oct; 31(28):3549-56. PubMed ID: 23980086
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the tolerability and pharmacokinetics of palifermin in children undergoing allogeneic hematopoietic stem cell transplantation.
Srinivasan A; Kasow KA; Cross S; Parrish M; Wang C; Srivastava DK; Cai X; Panetta JC; Leung W
Biol Blood Marrow Transplant; 2012 Aug; 18(8):1309-14. PubMed ID: 22542710
[TBL] [Abstract][Full Text] [Related]
15. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
16. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
17. Pilot study of prophylactic ex vivo costimulated donor leukocyte infusion after reduced-intensity conditioned allogeneic stem cell transplantation.
Kumar AJ; Hexner EO; Frey NV; Luger SM; Loren AW; Reshef R; Boyer J; Smith J; Stadtmauer EA; Levine BL; June CH; Porter DL; Goldstein SC
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1094-101. PubMed ID: 23635453
[TBL] [Abstract][Full Text] [Related]
18. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
[TBL] [Abstract][Full Text] [Related]
19. Palifermin for oral mucositis after intensive therapy for hematologic cancers.
Spielberger R; Stiff P; Bensinger W; Gentile T; Weisdorf D; Kewalramani T; Shea T; Yanovich S; Hansen K; Noga S; McCarty J; LeMaistre CF; Sung EC; Blazar BR; Elhardt D; Chen MG; Emmanouilides C
N Engl J Med; 2004 Dec; 351(25):2590-8. PubMed ID: 15602019
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Palifermin Use on Hematopoietic Cell Transplant Outcomes in Children.
Saber W; Zhang MJ; Steinert P; Chen M; Horowitz MM
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1460-1466. PubMed ID: 27090960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]